Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Study
100%
Sunitinib Malate
100%
Gynecologic Oncology Group
100%
Uterine Leiomyosarcoma
100%
Sunitinib
80%
Progression-free
60%
Binomial Confidence Interval
40%
Histology
20%
Thrombosis
20%
Tumor Progression
20%
Vomiting
20%
Diarrhea
20%
Doxorubicin
20%
Anemia
20%
Neutropenia
20%
Thrombocytopenia
20%
Tumor Response
20%
Lymphopenia
20%
Partial Response
20%
New Agents
20%
Time to Progression
20%
Objective Response
20%
Cardiac Ejection Fraction
20%
Hand-foot Syndrome
20%
Objective Tumor Response
20%
Leiomyosarcoma
20%
Tumor Vasculature
20%
Skin Rash
20%
Disease Stabilization
20%
Second-line Treatment
20%
Number of Cycles
20%
Third-line Treatment
20%
Median Progression-free Survival
20%
Gemcitabine/Docetaxel
20%
Estimated Time
20%
Hypertension Grades
20%
Targeting Tumor
20%
Medicine and Dentistry
Leiomyosarcoma
100%
Sunitinib
100%
Gynecological Oncology
100%
Progression Free Survival
66%
Neoplasm
33%
Diseases
16%
Thrombosis
16%
Lymphocytopenia
16%
Doxorubicin
16%
Neutropenia
16%
Diarrhea
16%
Anemia
16%
Thrombocytopenia
16%
Gemcitabine
16%
Docetaxel
16%
Ejection Fraction
16%
Hand Foot Syndrome
16%
Mouth
16%
Tumor Vascularization
16%
Exanthem
16%
Histology
16%
Hypertension
16%
Nursing and Health Professions
Leiomyosarcoma
100%
Sunitinib
100%
Progression Free Survival
66%
Neoplasm
33%
Confidence Interval
33%
Diseases
16%
Thrombocytopenia
16%
Hand Foot Syndrome
16%
Gemcitabine
16%
Neutropenia
16%
Doxil
16%
Anemia
16%
Tumor Vascularization
16%
Docetaxel
16%
Thrombosis
16%
Diarrhea
16%
Lymphocytopenia
16%
Heart Ejection Fraction
16%
Rash
16%
Histology
16%
Efficacy
16%
Hypertension
16%
Mouth
16%
Pharmacology, Toxicology and Pharmaceutical Science
Leiomyosarcoma
100%
Sunitinib
100%
Progression Free Survival
66%
Neoplasm
33%
Diseases
16%
Gemcitabine
16%
Doxorubicin
16%
Thrombocytopenia
16%
Diarrhea
16%
Neutropenia
16%
Docetaxel
16%
Rash
16%
Anemia
16%
Lymphocytopenia
16%
Thrombosis
16%
Hand Foot Syndrome
16%
Tumor Vascularization
16%
Hypertension
16%